Welcome to our dedicated page for TradeUP Acquisition news (Ticker: uptd), a resource for investors and traders seeking the latest updates and insights on TradeUP Acquisition stock.
TradeUP Acquisition Corp. (NASDAQ: UPTD) serves as your centralized hub for tracking developments following its landmark merger with Estrella Biopharma. This page aggregates official announcements and strategic updates from the newly formed Estrella Immunopharma, Inc. (NASDAQ: ESLA), providing investors and industry observers with timely insights into clinical progress and corporate milestones.
Access verified updates on therapeutic advancements in T-cell cancer treatments, partnership developments with leading biotech organizations, and financial positioning updates. Our curated news collection eliminates speculation by focusing exclusively on material disclosures and regulatory filings.
Key areas of coverage include clinical trial progress for EB103/CD19-targeted therapies, strategic collaborations in oncology research, and post-merger financial developments. Bookmark this page for streamlined access to essential updates about this innovative player in cancer immunotherapy.
On October 3, 2022, Estrella Biopharma announced a definitive business combination agreement with TradeUP Acquisition Corp. (NASDAQ: UPTD) dated September 30, 2022. This merger will result in Estrella becoming publicly listed as Estrella Immunopharma, Inc. Estrella specializes in CD19-targeted ARTEMIS®️ T-cell therapies for blood cancers and solid tumors, with lead candidates EB103 and EB104. The transaction anticipates a pro forma equity valuation of approximately $398.5 million, with TradeUP's shareholders retaining about 11.1% ownership post-merger. The deal is expected to close in the first half of 2023, pending approvals.
FAQ
What is the market cap of TradeUP Acquisition (uptd)?
